Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

• Status: Completed
• Trial end date: 2018-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 2 years from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion; Helsinn Therapeutics (U.S.), Inc
• Treatments: Mechlorethamine

Criteria

Inclusion Criteria:

• All adult patients (≥ 18 years of age) diagnosed with MF CTCL and being treated with Valchlor. This includes patients newly initiating Valchlor OR patients continuing treatment with Valchlor:

• Patients newly initiating Valchlor are patients who have their first office visit after having initiated Valchlor.

• Patients continuing treatment with Valchlor includes patients who are actively taking Valchlor on the day of enrollment.

• Signed patient informed consent.

Exclusion Criteria:

• None